| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Pathology, University of Michigan, Ann Arbor, MI 48109; and
Pathology and Experimental Toxicology and Biotechnology Department, Parke-Davis Pharmaceutical Research, Warner-Lambert Co., Ann Arbor, MI 48105
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and
chemokines were not affected by treatment with anti-TIMP-2 or
anti-SLPI. The data suggest that endogenous TIMP-2 and SLPI
dynamically regulate the intensity of lung inflammatory injury, doing
so at least in part by affecting the generation of the inflammatory
mediator, C5a. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Another naturally occurring protease inhibitor, secretory leukocyte
protease inhibitor (SLPI), is a constitutively expressed,
up-regulatable inhibitor of serine proteases. SLPI was originally
isolated from parotid saliva 15 . Human SLPI exists as a
nonglycosylated 12-kDa protein 16 . Murine SLPI has also been cloned
recently and exhibits a high content of cysteine residues, 16 in all
17, 18 . SLPI is found in extrapulmonary secretory fluids 15, 19 and
in skin and articular cartilage 20 . By immunostaining, SLPI has also
been detected in serous cells of salivary glands, in airway surface
epithelial cells, in Clara cells of the bronchial epithelium, and in
association with elastin fibers of the lung interstitium 21, 22, 23 .
Serine proteases inhibited by SLPI include neutrophil elastase,
cathepsin G, chymotrypsin, chymase, and trypsin 22, 24 . SLPI has been
shown recently to inhibit replication of HIV-1 in cultured human
monocytes 25 . In addition, it has been reported that
transgene-induced production of SLPI reduces TNF- production in
LPS-stimulated phagocytic cells 17 . Other local anti-proteases
include anti-trypsin, Elafin, and anti-chymotrypsin, to
name but a few.
The balance between oxidants and antioxidants and between proinflammatory and anti-inflammatory cytokines together with proteases and antiproteases in the inflamed lung probably determines the outcome of an inflammatory insult 24, 26, 27 . It is known that the breakdown of elastin and collagen can result in the appearance of peptides that are chemotactic for neutrophils 28, 29, 30 . It is also likely that MMPs and serine proteases directly attack connective tissue matrix proteins, causing structural damage in the inflamed tissue. In experimental studies, exogenously administered recombinant human SLPI and TIMP-2 were shown to reduce the intensity of lung inflammatory injury after deposition of IgG immune complexes in a manner associated with reduced accumulation of neutrophils, implying that TIMP-2 and SLPI somehow regulate neutrophil influx 31 . Recently, there have been suggestions that SLPI regulates the intensity of elastase-induced pulmonary emphysema 32 .
Because it is likely that MMPs and serine proteases play a determinative role in the outcome of lung inflammatory injury, we developed cDNA probes and Abs to rat TIMP-2 and SLPI and employed these in studies of IgG immune complex-induced alveolitis. Our results suggest that both endogenous TIMP-2 and SLPI are up-regulated during lung inflammation and govern the intensity of inflammatory lung injury. The administration of polyclonal Abs to rat TIMP-2 or SLPI resulted in intensified lung injury associated with enhanced recruitment of neutrophils. It appears that MMPs and serine proteases in lung may contribute to the generation of C5a, the production of which enhances the recruitment of neutrophils and intensifies the attendant lung injury.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Except where noted, all reagents were purchased from Sigma (St. Louis, MO).
Rat model of acute lung injury
Lung injury was induced in rats as previously described, using a well-characterized model of IgG immune complex-mediated alveolitis 33, 34 . Briefly, 275- to 300-g male Long-Evans rats (specific pathogen free, Harlan Industries, Rochester, MI) were anesthetized with i.p. administered ketamine (60–80 mg/kg). This model of injury, which is associated with structural damage of endothelial and alveolar epithelial cells, has been described in detail previously 33 . Injury was induced by the intratracheal instillation of rabbit polyclonal IgG containing precipitating Ab to BSA (anti-BSA) in a volume of 300 µl of PBS, pH 7.4. Immediately thereafter, 10 mg of BSA together with trace amounts of [125I]BSA (as a quantitative marker of permeability) were injected i.v. Rats were sacrificed 4 h later, and the pulmonary arterial circulation was flushed with 10 ml of PBS. The lungs were surgically dissected, and the amount of remaining radioactivity (125I-labeled BSA) was determined to assess the permeability index. Negative control animals received anti-BSA intratracheally without i.v. administered BSA. For calculations of the permeability index, the amount of radioactive [125I]BSA remaining in PBS-perfused lungs was compared with the amount of radioactivity present in 1.0 ml of blood obtained from the inferior vena cava at the time of sacrifice.
Bronchoalveolar lavage (BAL) fluid analysis
At the times indicated, lungs were lavaged thrice with 8 ml of
PBS via an intratracheal cannula. BAL fluids were collected, and
neutrophil content was determined by conventional microcytometry. BAL
fluid supernatants were evaluated for TNF- activity using a standard
WEHI cell cytotoxicity bioassay 34 and for chemokine content and C5a
as described below.
Cloning of rat TIMP-2
IgG immune complex-induced injury in rats was accomplished as described above. At the indicated time points, whole lungs were immediately dissected and frozen in liquid nitrogen. Total RNA was extracted from whole lung homogenates using a guanidinium isothiocyanate/chloroform-based technique (RNA STAT-60, Tel-Test, Friendswood, TX) followed by isopropanol precipitation. mRNA was purified on oligo(dT)-cellulose. First-strand cDNAs were constructed from 1 µg of mRNA with a RT reaction primed with a poly(dT) primer (cDNA Cycle Kit, Invitrogen, San Diego, CA). Rat TIMP-2 cDNA was PCR amplified using the following oligonucleotide primers: 5' primer, 5'-ATG GGC GCC GCG GCC CGC-3'; and 3' primer, 5'-TTA CGG GTC CTC GAT GTC AAG AA-3'. After ligation into a pCRII Vector (TA Cloning Kit, Invitrogen), the PCR product was sequenced in both directions from the vector’s T7 and SP6 promoter regions for comparison to the known murine sequence 12 . This sequence was confirmed with a clone independently generated from a second IgG immune complex-injured rat lung.
Expression and purification of rat TIMP-2
EcoRI (5') and BamHI (3') restriction enzyme sites were added by PCR to the 5' and 3' ends of the cDNA encoding the mature protein for TIMP-2 followed by ligation into the pET15b expression vector (Novagen, Madison, WI). After ligation, pET-TIMP-2 plasmids were transformed into competent Nova Blue Escherichia coli. The pET-TIMP-2 plasmids were purified, sequenced, and then used for transformation of BL21 (DE)pLysS E. coli strains. These bacterial cultures were used for optimization of isopropyl ß-D-thiogalactoside-stimulated overexpression of recombinant TIMP-2 according to a previously described procedure 35 . Recombinant rat TIMP-2 was purified to homogeneity using an immobilized metal ion (nickel) affinity chromatography column (Novagen) under nondenaturing conditions.
Characterization of TIMP-2 expression products from E. coli
Proteins expressed by pET15b-transformed E. coli recombinants were subjected to SDS-PAGE (17%) under reducing conditions according to the method of Laemmli 36 . The separated proteins were transblotted onto nitrocellulose (0.45 µm; Bio-Rad, Hercules, CA) for 2 h at 12 V. Following transfer, the membrane was blocked with 3% BSA in 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, and 0.05% Tween-20 (v/v) for 2 h at room temperature and developed with anti-rat TIMP-2 Ab. Recombinant rat TIMP-2 contained an N-terminal His tag. The product was isolated by elution from a nickel affinity column with imidazole and analyzed by Western blot analysis using anti-rat TIMP-2. The Ab reacted with recombinant human TIMP-2 and defined a single band near the 18.5-kDa marker (data not shown).
Measurement of metalloproteinase activity by gel zymography
BAL fluids were obtained 0 and 4 h after initiation of lung injury. They were then precleared of any residual IgG that was used to initiate lung injury by incubation with Gammabind Sepharose beads (Amersham, Arlington Heights, IL). BAL fluids were then incubated with 10 µg of either anti-rat TIMP-2 IgG or control nonspecific IgG. These were then further incubated with Gammabind Sepharose beads. The beads were then washed with PBS before the addition of SDS-PAGE sample buffer in the absence of 2-ME. SDS-PAGE substrate-embedded enzymography (zymography) was performed using modifications of the procedure of Heusen and Dowdle 37, 38 . Electrophoresis was conducted in 7.5% acrylamide gels containing 1 mg/ml gelatin. Nonreduced samples and standards were run at a constant voltage (150 V) until the dye front reached approximately 0.5 cm from the bottom of the gels. The gels were then subjected to the following washing protocol: twice for 15 min in 50 mM Tris buffer, pH 7.6, containing 2.5% Triton X-100, and once for 5 min in 50 mM Tris buffer, pH 7.6, alone, then incubated overnight at 37°C in 50 mM Tris buffer, pH 7.6, containing 1.0% Triton X-100. Gels were stained with Coomassie brilliant blue 250-R for several hours and then destained to reveal zones of enzyme activity, which appeared as bands of clearing.
Cloning of rat SLPI cDNA
IgG immune complex-induced injury in rats and RNA extraction and isolation were performed as described above. First-strand cDNAs were constructed from 1 µg of mRNA with a RT reaction primed with poly(dT) primers (cDNA Cycle Kit, Invitrogen). Rat SLPI was PCR amplified using the RT reaction product as template together with a 5' oligonucleotide primer (5'-ATG AAG TCC AGC GGC CTC TTC-3') constructed from the human SLPI sequence and a 3' oligonucleotide primer that was degenerate for the human sequence (5'-(C/T)(C/T)A (A/C/G/T)GC (C/T)TT (A/C/G/T)AC (A/C/G/T)GG (A/C/G/T)(G/C)(A/T) (A/C/G/T)AC (A/G)CA-3'; residues in parentheses indicate nucleotide degeneracy). Additional oligonucleotide primers were constructed to sequences within the rat SLPI open reading frame (5'-AAG AAG AGA TGT TGT CCT GAC ACT-3' and 5'-GCA GGA TTT CCC ACA CAT GCC-3') and used for internal sequence confirmation. After ligation into a pCRII vector (TA Cloning Kit, Invitrogen), the inserted PCR product was sequenced bidirectionally from the vector’s T7 and SP6 promoter regions and compared with the human sequence 15, 16 . This procedure was performed in triplicate, producing three independent clones of the SLPI sequence from IgG-immune complex-injured rat lungs, with identical sequence results.
Rabbit polyclonal anti-TIMP-2 and anti-SLPI IgG
Polyclonal rabbit Ab was raised against recombinant rat TIMP-2 or against a BAL protein recognized by anti-human SLPI. Because recombinant rat SLPI was extremely resistant to solubilization procedures, we used BAL fluids from IgG immune complex-injured lungs. Western blot analysis with polyclonal anti-human SLPI recognized a band from BAL fluids very close to the 12-kDa position. New Zealand White rabbits were repeatedly immunized with approximately 10 µg of purified rat TIMP-2 or rat SLPI extracted from gel slices. The gel slices or purified protein were emulsified in CFA and subsequently in IFA. The resulting antisera were purified with a protein G-Sepharose column (Pharmacia, Piscataway, NJ). Immune serum was diluted 1/1 with PBS and applied to the column. After 1-h incubation at 4°C and extensive washing with PBS, the column was stripped by addition of 100 mM glycine-HCl, pH 2.7. Eluted fractions (1 ml) were collected in tubes containing 200 µl of 1 M Tris buffer, pH 8.0. The purified IgG fraction was then dialyzed against PBS. For determination of serum titers of Ab, an indirect ELISA was used. Briefly, a 96-well Immulon-4 ELISA plate (Dynatech, Chantilly, VA) was coated with soluble recombinant rat TIMP-2 or human SLPI (5 µg/ml) overnight at 4°C. Plates were blocked with 2% BSA in PBS for 1 h before addition of serial dilutions of rabbit anti-TIMP-2 or anti-SPLI serum. The plate was washed, and 100 µl/well horseradish peroxidase-conjugated goat anti-rabbit Abs (1/3000 dilution; Bio-Rad) were incubated with samples. The reaction was developed with orthophenylenediamine dihydrochloride substrate and was stopped with 3 M H2SO4. Titers, which were determined by measuring absorbance at 490 nm, were approximately 106.
Detection of TIMP-2 and SLPI proteins in BAL samples
Aliquots of the BAL samples obtained at various time points from lung-injured rats were analyzed by Western blot for protein immunoreactive with rabbit anti-rat TIMP-2 and/or anti-rat (or goat anti-human) SLPI. Two milliliters of BAL fluid was concentrated 10-fold using Centricon-3 microconcentrators (Amicon, Beverly, MA), with centrifugation at 7500 x g for 6–10 h. Five microliters of Laemmli’s buffer was added to 20 µl of each concentrated sample and analyzed by SDS-PAGE in adjacent lanes, then transferred to nitrocellulose (Bio-Rad). When nonreducing conditions were used, sample buffer without SDS or 2-ME was added to the concentrated BAL samples and analyzed on polyacrylamide gels before transfer to nitrocellulose membrane. The membrane was then blocked with 5% nonfat dry milk in Tris-buffered saline/Tween-20. It was then incubated with anti-rat TIMP-2 or anti-SLPI diluted 1/1000. After incubation with a 1/1000 dilution of a secondary Ab (goat anti-rabbit or rabbit anti-goat conjugated to alkaline phosphatase), the blot was developed with alkaline phosphatase color reagents A and B (Bio-Rad).
TIMP-2 and SLPI mRNA expression in lung homogenates
Whole lungs of rats following IgG immune complex deposition were obtained between 0 and 8 h following initiation of injury and frozen in liquid nitrogen for RNA extraction. RNA was fractionated electrophoretically in a 1% formaldehyde gel and transferred to a nylon membrane (Zetabind, Cuno, Meridian, CT). Specific primers and the respective cDNA templates for TIMP-2 and SLPI were used to generate 32P-labeled probes by PCR. Hybridization was performed at 65°C for 16 h. Autoradiography was performed at -70°C on Kodak X-OMAT-AR film (Rochester, NY). A Fotodyne densitometer (New Berlin, WI) with AMBIS software (San Diego, CA) was used for densitometry analysis. Equal RNA loading was confirmed by methylene blue staining of 18S and 28S bands.
Biotinylation of rabbit polyclonal anti-rat TIMP-2 and anti-rat SLPI IgG
Anti-rat TIMP-2 or anti-rat SLPI (2.0 mg) was dialyzed in PBS overnight at 4°C in 50 mM sodium bicarbonate buffer, pH 8.5. NHS-LC-Biotin (74 µg; Pierce, Rockford, IL) was added to IgG preparations and incubated on ice for 2 h. The material was dialyzed in 20 mM Tris (pH 7.5), 150 mM NaCl, and 0.02% sodium azide overnight at 4°C to remove unreacted biotin.
Immunohistochemical staining
Rat lungs were obtained after IgG immune complex deposition, as described above. Optimal cutting tissue compound (OCT, Tissue-Tek, Miles, Elkhart, IN) was instilled intratracheally into lungs, which were then snap-frozen and stored at -70°C. Cryostat sections of frozen lungs were fixed in cold acetone for 10 min, followed by three rinses in PBS. To quench endogenous peroxidase activity, tissue sections were incubated with 0.3% H2O2 in methanol for 30 min at room temperature. Thereafter, slides were incubated with normal rabbit serum diluted 1/20 to block nonspecific staining. After rinsing with PBS, the slides were incubated with biotinylated rabbit anti-rat TIMP-2 and anti-rat SLPI IgG (each at 5 µg/ml) in PBS supplemented with 1% BSA for 30 min at room temperature and rinsed with PBS three times, for 5 min each time. Normal rabbit or goat IgG was used as a negative control. Slides were incubated 30 min with the avidin-biotin enzyme reagent (Vectastain ABC Kits, Vector Laboratories, Burlingame, CA), and the reaction was visualized using 0.01% H2O2 containing 0.05% 3,3'-diaminobenzidine tetra-hydrochloride (Sigma). The sections were counterstained with hematoxylin.
Chemotaxis and chemokine assays
BAL fluids were evaluated for neutrophil chemotactic activity. For convenience, human neutrophils were isolated from acid citrate dextrose-treated human whole blood by a Ficoll-Paque (Pharmacia) gradient. Following dextran sedimentation and hypotonic RBC lysis, the cells were treated with 2',7'-bis(2-carboxyethyl)-5-(and-6)-carboxy-fluorescein acetoxymethyl ester (Sigma). A 96-well minichamber was used for chemotaxis assays as previously described 39 . Neutrophils (2.25 x 105/well) were loaded into upper compartments of polycarbonate filters containing a porosity of 3 µm. Cells were incubated for 30 min at 37°C (5% CO2, humidified). The filter was removed, and nonmigrating cells wiped off. Fluorescence was read on a Cytofluor 2300 plate reader (Perseptive Biosystems, Framingham, MA) at 630 nm. FMLP (10-6–10-9 M) was used as a positive control for all chemotaxis studies. The BAL content of rat CXC chemokines, MIP-2 and cytokine-induced neutrophil chemoattractant (CINC), was determined by ELISA. The 2 h time was selected because this is when BAL levels of MIP-2 and CINC peak 39 . C5a functional activity in BAL fluids was defined by the use of rabbit anti-C5a, which blocks neutrophil chemotactic activity of rat C5a 40 . For this study normal rabbit IgG or anti-rat C5a IgG (each at 5 µg/ml) was added to the BAL fluids before the chemotaxis assay. For calculation of change inhibition in chemotactic activity, values for negative controls were subtracted from all positive control groups, and then the present reduction was calculated for comparisons between positive control groups.
Statistical analysis
All values were expressed as the mean ± SEM. Datasets were examined with one- and two-way analysis of variance, and individual group means were then compared with Student’s t test. For calculations of the percent change, mean negative control values were first subtracted from values in positive control groups and in each treatment group.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Rat TIMP-2 has been cloned by other groups 13, 14 . Our rat TIMP-2 cDNA demonstrated >99% identity with the published rat nucleotide and amino acid sequences, with a 663-nucleotide open reading frame that was 96 and 92% homologous to the murine 12 and human 7, 11 TIMP-2 sequences, respectively (data not shown). The open reading frame encoded a 220-amino acid peptide with a 26-amino acid signal peptide and a mature protein consisting of 194 amino acids. The deduced amino acid sequence shared 99 and 97% homology with the published murine and human sequences for TIMP-2, respectively (data not shown). Analysis of the protein structure revealed an estimated molecular mass of 20 kDa.
TIMP-2 mRNA time course in IgG immune complex-induced lung injury
Expression of mRNA for TIMP-2 in lung extracts from animals
undergoing lung injury due to intrapulmonary deposition of IgG immune
complexes was determined as a function of time (0–6 h) after
initiation of injury. RNA was analyzed by Northern blots probed with a
full-length radiolabeled cDNA for rat TIMP-2. Results are shown in Fig. 1
, in which relative OD as a function of
time was determined in lung extracts. Equal loading was demonstrated by
methylene blue staining of 18S and 28S bands (upper frame
inset). While constitutive expression was found in lung RNA,
maximal up-regulation was found 0.5 h after initiation of the lung
inflammatory reaction, with up-regulation continuing to 4 h,
followed by a decrease at 6 h. Northern blot analysis showed
distinct TIMP-2 mRNA transcripts of 1.0 and 3.5 kb (Fig. 1, bottom frame), as has been previously reported for human 7, 11 and murine 12 TIMP-2. Recent data demonstrate that the difference
in size of the mRNAs of the human TIMP-2 gene is the result of the use
of different polyadenylation signals within the 3' end of the gene
41 .
|
In gels in which electrophoresis was performed under reducing
conditions, Western blot analysis was conducted with anti-rat
TIMP-2. TIMP-2 was not detected in BAL fluids obtained at time zero
(Fig. 2), but was detected in BAL fluids
in a position near the 18.5-kDa marker at 0.5, 1, 2, 4, 6, and 8 h
after initiation of lung inflammatory responses. The m.w. standards are
shown in the extreme left lane. Anti-rat TIMP-2
demonstrated reactivity for both the recombinant rat and human TIMP-2
(Fig. 2, extreme right two lanes). Under nonreducing
conditions anti-TIMP-2 Ab detected at the 4 h point a band of
approximately 110 kDa (data not shown). This finding suggests that
TIMP-2 exists as a complex with an enzyme(s) in the inflamed lung.
|
The deduced nucleotide and amino acid sequences derived from three
independently cloned rat SLPI cDNAs are shown in Fig. 3. The first 21 bases of the sequence
represent the primer that was used to clone the cDNA. The predicted
open reading frame encodes a mature protein of 106 amino acids with an
estimated molecular mass of 14 kDa. The first 25 amino acids form the
putative signal peptide. Further analysis of the deduced amino acid
sequence revealed 67% homology with human SLPI and 91% homology with
murine SLPI amino acid sequences, with all 16 cysteine residues
conserved (Fig. 4).
|
|
Expression of mRNA for SLPI in lung extracts from animals
undergoing lung injury was determined as a function of time (0–8 h)
after initiation of the reaction (Fig. 5). The pattern was different from that
found for rat TIMP-2 (Fig. 1
). mRNA for rat SLPI was analyzed by
Northern blot probed with a full-length open reading frame cDNA for rat
SLPI. The results are shown in Fig. 5, A and B,
in which the time course of expression (after normalization of signals
as explained in Materials and Methods) was determined in the
IgG immune complex model of lung injury (Fig. 5B). Normal
lung (at 0 h) contained no detectable mRNA for SLPI; very little
mRNA could be detected at 1 and 2 h, but there was a gradual
increase in expression of lung SLPI mRNA, especially at 4 h and
continuing to at least 8 h (Fig. 5A). Northern blot
analysis showed only one mRNA transcript of 0.7 kb for rat SLPI.
|
Immunoreactive SLPI material was detected by Western blot analysis
of BAL fluids at 0.5, 1, 2, 4, 6, and 8 h after initiation of the
lung inflammatory reactions (Fig. 6). No
constitutive SLPI was found in BAL fluids (obtained at time zero). The
bands in BAL samples closely aligned with recombinant human SLPI. In
data not shown, recombinant human and rat SLPI aligned in the same
position. Under nonreducing conditions anti-SLPI Ab detected a band
of approximately 115 kDa (data not shown) at the 4 h point,
suggesting that SLPI exists as a complex with its substrate in the
inflamed lung.
|
Rabbit polyclonal blocking Abs to rat TIMP-2 and SLPI were used to
assess the extent to which their intratracheal instillation would alter
the severity of inflammatory lung injury. Negative control animals
received anti-BSA intratracheally in the absence of i.v. injected
BSA. In positive controls, unless otherwise indicated, 250–300 µg
preimmune IgG was mixed with the anti-BSA. In all studies
anti-TIMP-2 or anti-SLPI in the indicated amounts was instilled
intratracheally with the anti-BSA. The intensity of the lung injury
was assessed by the permeability index and by neutrophil counts in BAL
fluids. The results from five separate experiments are summarized in
Table I. The presence of anti-TIMP-2
Ab (Expt. A–C) caused a significant increase (29–52%) in the
intensity of the lung injury, as reflected by extravascular leak of
albumin, compared with that in the positive control animals treated
with preimmune IgG. Increasing the dose of anti-TIMP-2 to 500 or
1000 µg did not further increase the permeability index (data not
shown). In experiments not shown, negative controls that received
anti-BSA intratracheally, but with omission of the i.v. infusion
of 10 mg of BSA, and that also received 300 µg of
anti-TIMP-2 or anti-SLPI intratracheally had permeability
indexes that were the same as those found in otherwise untreated
negative control animals (data not shown). The effect of anti-TIMP2
on neutrophil content of BAL fluids was also assessed. As shown in
Table I, compared with animals receiving preimmune IgG there was a
significant increase in BAL neutrophils in animals receiving
anti-TIMP 2, rising from 85–115%, depending on the particular
experiment.
|
, Expt. D and E). The instillation of SLPI Ab in two separate
experiments markedly increased the permeability index, rising from
56–85% compared with that in positive control animals receiving
preimmune IgG. Treatment with anti-SLPI induced an increase in the
permeability index that appeared to be dose dependent, with 250 and 500
µg of the Ab causing 54 and 85% increases, respectively, in the
permeability index. In terms of BAL neutrophil counts, treatment with
anti-SLPI Ab caused significant increases in the number of BAL
neutrophils (53–81%) compared with that in the positive control
groups treated with preimmune IgG. Chemotactic activity in BAL fluids
To assess the possible mechanism(s) by which treatment of animals
with anti-TIMP-2 or anti-SLPI caused increased neutrophil
accumulation, BAL fluids were examined 2 and 4 h after the
initiation of lung inflammatory reactions for chemotactic activity for
neutrophils. Total chemotactic activity, chemokine content (MIP-2 and
CINC), and C5a-related chemotactic activity were determined. As shown
in Table II, there was a >20-fold
increase in overall chemotactic activity in BAL fluids at both 2 and
4 h following initiation of the inflammatory reaction in the
positive control group treated with 300 µg of preimmune IgG. In the
presence of either anti-TIMP-2 or anti-SLPI, no significant
increase (<5%) in chemotactic activity occurred at 2 h. However,
at 4 h, treatment with anti-TIMP-2 caused a 1.70-fold increase
(p = 0.001) in chemotactic activity, while
treatment with anti-SLPI caused a 1.64-fold increase
(p = 0.02) in chemotactic activity compared
with the values in the positive controls treated with preimmune IgG.
Thus, the increase in neutrophil accumulation in BAL fluids under these
experimental conditions correlates with increased chemotactic activity
in BAL fluids at 4 h.
|
Chemokine content in BAL fluids was assessed at 2 h, as this
is the time at which MIP-2 and CINC levels peak in the lung
inflammatory model employed 39 . As shown by the data in Table III, MIP-2 levels increased by nearly
fivefold in the positive controls pretreated with preimmune IgG
compared with those in negative controls. Likewise, CINC levels
increased threefold in the positive controls pretreated with preimmune
IgG. In the presence of anti-TIMP-2 or anti-SLPI, no further
increase in chemokine content appeared. While there were slight
increases in CINC levels in animals treated with anti-TIMP-2 or
anti-SLPI, these were not statistically significant compared with
levels in positive controls treated with preimmune IgG. Thus, increased
lung injury and increased levels of neutrophils in BAL fluids of
positive controls treated with anti-TIMP-2 or anti-SLPI were
not reflected by increases in BAL CXC chemokines.
|
To assess to what extent chemotactic activity in BAL fluids of
positive control animals at 2 and 4 h could be related to C5a
content, the experiments described in Table IV were conducted. Two and four hour BAL
fluids from negative controls (in which i.v. infusion of BSA was
omitted) had chemotactic values, as revealed by relative fluorescence
units of <10 (data not shown). Similar to the findings described in
Table II, at 2 h there were >20-fold increases in chemotactic
activity in each of the three positive control groups. The addition of
anti-C5a IgG (5 µg/ml) failed to reduce the chemotactic activity
in the 2 h BAL samples compared with companion samples to which
were added preimmune IgG (5 µg/ml; Table IV). In the BAL fluids
obtained at 4 h, chemotactic activity was significantly increased
(nearly doubled) in all three positive control groups compared with
that in BAL fluids obtained at 2 h, and these increases were
statistically significant. The total amount of chemotactic activity in
the 4 h samples from positive control rats treated with preimmune
IgG was significantly higher than that at 2 h (368 ± 46 vs
212 ± 14). The 4 h BAL samples from animals pretreated with
anti-TIMP-2 or anti-SLPI contained significantly
(p < 0.05) elevated levels (by 52–57%) of
chemotactic activity compared with the 4 h BAL samples from rats
treated with preimmune IgG. In all three positive control groups, the
addition of anti-C5a to 4 h BAL fluids substantially reduced
the level of measurable neutrophil chemotactic activity, from 76 to
90% (p = < 0.05). Thus, the increased
chemotactic activity in 4 h BAL fluids of animals treated with
anti-TIMP-2 or anti-SLPI appeared to be associated
predominately with increased C5a-dependent chemotactic activity.
|
TNF- activity in BAL fluids
BAL levels of TNF- were evaluated at 2 and 4 h using
treatment protocols similar to those described in Tables I–IV. TNF-
levels rose from <30 pg/ml in the negative control group to 2300
± 1200 and 6427 ± 1518 pg/ml at 2 and 4 h, respectively, in
the positive control groups pretreated with 300 µg of preimmune IgG
(data not displayed). In positive control groups pretreated with
anti-TIMP-2, BAL levels at 2 and 4 h were 1900 ± 240 and
9335 ± 629 pg/ml, respectively, while 2 and 4 h BAL fluids
from anti-SLPI-treated animals had values of 2100 ± 1500 and
7632 ± 768, respectively. When TNF- levels at 2 and 4 h
in the positive control groups (which also received 300 µg of
preimmune IgG with the anti-BSA) were compared with the values at
the same time points in animals receiving either 300 µg of
anti-TIMP-2 or 300 µg of anti-SLPI, there were no
statistically significant differences. Thus, treatment with
anti-TIMP-2 or anti-SLPI did not significantly affect BAL
levels of TNF-.
Expression of TIMP-2 and SLPI in rat lungs
Immunostaining for TIMP-2 and SLPI was conducted using frozen
sections of rat lungs at 0 and 4 h. The results are shown in Fig. 7. In the case of TIMP-2, no staining was
found in lungs obtained at time zero either in vessels (Fig. 7A,
upper area) or in bronchioles (Fig. 7A, lower area). In
striking contrast, at 4 h (Fig. 7B) staining for TIMP-2
was found in alveolar epithelial cells (arrowheads) and in endothelial
cells (arrow). In the case of SLPI, no staining was found in lung
tissue at 0 h (Fig. 7C), whereas at 4 h staining
for SLPI was found on surfaces of alveolar epithelial cells (Fig. 7D, solid arrowheads), in vascular endothelial cells (solid
arrows), and in cells that appeared to be macrophages (open arrow). As
indicated above, the appearance of SLPI in BAL fluids (Fig. 2) seems
somewhat discordant with the appearance of mRNA for SLPI (Fig. 5). It
is possible that SLPI is generated in two waves, the first being early
(1–2 h) and involving alveolar macrophages, and the second involving
other cell types, such as endothelial and epithelial cells. This could
explain the differences in protein presence (in BAL fluids) and mRNA
appearance (in whole lung homogenates).
|
To ascertain whether there was any metalloproteinase activity
associated with TIMP-2, BAL fluids were obtained 0 and 4 h after
initiation of lung injury. Zymography was performed after incubating
samples with anti-TIMP-2 Ab or nonspecific IgG and Gammabind
Sepharose beads. No MMP-2 or MMP-9 activity was found to be associated
with anti-TIMP-2 Ab at the 0 h point (Fig. 8). However, at 4 h both MMP-2 and
MMP-9 activities were associated with the anti-TIMP-2 Ab (Fig. 8),
but not with the control nonspecific IgG (data not shown), thus
confirming that complex formation does take place between TIMP-2 and
MMPs in BALs from injured lungs.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
48 . The in vivo finding of
complexes of SLPI with human neutrophil elastase in bronchial
secretions suggests that SLPI functions as an elastase inhibitor 24, 47, 48 . Collectively, it seems likely that the balance of endogenous
proteases and anti-proteases (TIMPs and SLPI) in lung at least in
part determines the outcome of inflammatory-induced lung injury, but
there is little direct evidence to support this conclusion. Recent studies suggest that membrane-type MMPs are also regulated by TIMP-2 49, 50 . Therefore, the activity of a given MMP in vivo may depend directly on the tissue level and availability of TIMP-2. Since MMP expression has been correlated with invasiveness of tumor cells, it has been suggested that the ability of tumor cells to cross basement membranes may partly be due to the expression of MMPs 51, 52 .
As demonstrated in the current studies, the rat SLPI gene encodes a
protein of 106 amino acids, with a 25-amino acid-containing signal
peptide. Comparison of the deduced amino acid sequence of rat SLPI to
the established sequences of human 15, 16 and murine SLPI 17, 18
has revealed 67 and 91% homologies, respectively. In our studies,
Northern blot analysis has shown SLPI mRNA in inflamed rat lung with an
approximate size of 0.7 kb, similar to that reported for human SLPI
20, 53 . There are few studies describing in vivo expression of SLPI
or TIMP-2 in lung inflammatory responses, although several reports
describe protective effects of exogenously administered SLPI in lung
models of injury 31, 54, 55, 56, 57 . SLPI has also been reported to function
as an anti-inflammatory agent by interfering with the signal
transduction pathway leading to monocyte metalloprotease production
58 . SLPI also inhibits TNF- in vitro responses of macrophages to
LPS 17 .
Recent work has demonstrated that intratracheal administration of
recombinant human TIMP-2 or SLPI results in suppression of IgG immune
complex-induced alveolitis 31 . This attenuation was unexpectedly
associated with a reduction in lung myeloperoxidase content,
suggesting that MMPs and serine proteases somehow affect neutrophil
recruitment and that this cell recruitment process may be regulated by
TIMP-2 and SLPI, as defined by exogenous administration of TIMP-2 or
SLPI. The data in the current studies indicate that both mRNA and
protein for TIMP-2 and SLPI are up-regulated during the course of the
lung inflammatory response, and that synthesis of these proteins is not
confined to a single cell type. The data show that Ab-induced blockade
of endogenous TIMP-2 or SLPI leads to intensified lung damage following
deposition of IgG immune complexes. Endogenous TIMP-2 and SLPI seem to
regulate the inflammatory response by attenuating the development of
tissue injury and by regulating the recruitment of neutrophils. The
enhanced recruitment of neutrophils in the presence of anti-TIMP-2
or anti-SLPI was not related to increased levels in BAL fluids of
CXC chemokines (MIP-2 and CINC) or TNF-, each of which is known to
be required for neutrophil recruitment in the lung injury model 34, 39 . However, enhanced neutrophil recruitment in the presence of
anti-TIMP-2 or anti-SLPI appears to be due to the increased
C5a-related neutrophil chemotactic activity present in BAL fluids at
4 h. Since it is well established that serine proteases from
neutrophils can generate a neutrophil chemotactic fragment from C5
59 , these data suggest that endogenous MMPs and serine proteases may
also have the ability to cleave C5 in a similar manner, producing C5a.
In the current studies, the Northern blot data have indicated induction
of mRNA for TIMP-2 (data not shown) and SLPI following intrapulmonary
deposition of IgG immune complexes, although the time course for
up-regulation was not the same for the two endogenous
anti-proteases. Western blot analysis of BAL fluids has revealed
up-regulation of both TIMP-2 and SLPI during the inflammatory response.
Immunostaining has shown localization of these inhibitors in alveolar
epithelial and vascular endothelial cells and in what appear to be lung
macrophages. The ability of blocking Abs to rat TIMP-2 or SLPI to
significantly increase neutrophil recruitment and to increase the
intensity of injury (as measured by leakage of serum albumin) suggests
that these inflammatory responses are indeed regulated by endogenous
enzyme inhibitors of MMPs and serine proteases, namely, TIMP-2 and
SLPI, respectively. Our data clearly indicate that MMP-2 and MMP-9 are
complexed to TIMP-2 in the injured lung. The data also indicate that
TIMP-2 and SLPI retrieved from the inflamed lung are present in
macromolecular forms, consistent with enzyme inhibitor complexes. The
apparent Mr of the TIMP-2 complexes detected
under nonreducing conditions was approximately 110 kDa. Given the
inherent limitations of Mr estimates using
electrophoretic gels, this would be consistent with a 1:1 molar ratio
of MMP-2 and TIMP-2 59 . The estimated 115 kDa value for SLPI (data
not shown) could be due to the fact that SLPI forms stable noncovalent
complexes with its substrates and other associated molecules. For
example, SLPI forms a complex with elastase and that is also bound to
2m 60 . Further, TIMP-2 and SLPI macromolecular
complexes could be cross-linked in the presence of oxidants generated
from activated phagocytic cells during the acute inflammatory
response, leading to larger than expected enzyme inhibitor
complexes.
The significant increase in C5a-related chemotactic activity as a
result of treatment with anti-TIMP-2 or anti-SLPI suggests that
enzymes regulated by these endogenous inhibitors facilitate the
cleavage of C5 to generate C5a. As indicated above, there is evidence
that neutrophils contain within lyosomal granules a C5-cleaving enzyme
that is capable at neutral pH of generating chemotactic activity 61 .
It is likely that this is a serine protease, which would be inhibitable
by SLPI. Based on the data in Table IV, it also seems likely that there
exists another C5 cleaving enzyme that can be blocked by TIMP-2. This
might imply that a MMP contains such an activity, although there are no
data that would directly support this possibility. Alternatively,
TIMP-2 might in some manner regulate the extent of activation of the
complement system, although no direct evidence for this possibility
exists. The requirement for neutrophil recruitment into lung to provide
the source of the C5 cleaving serine protease and, perhaps, the role of
a lung macrophage MMP in cleavage of C5 could explain why C5a levels
peak later (at 4 h, Fig. 4) than chemokine levels (Table III)
39 . To what extent chemotactic peptides from elastin or collagens may
also contribute to neutrophil recruitment in this lung injury model has
yet to be determined. What does seem clear from the current studies is
that TIMP-2 and SLPI regulate and control the intensity of the lung
inflammatory response, as shown by the up-regulation of these protease
inhibitors during the course of the inflammatory reaction and by the
exaggerated inflammatory response in the presence of either
anti-TIMP-2 or anti-SLPI. These data support the idea that
endogenous protease inhibitors regulate the lung inflammatory response
and suggest at least one mechanism by which this process occurs.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Peter A. Ward, Department of Pathology, University of Michigan Medical School, M5240 Medical Science I, Box 0602, 1301 Catherine Rd., Ann Arbor, MI 48109-0602. E-mail address:
3 Abbreviations used in this paper: MMP, matrix metalloprotease; TIMP, tissue inhibitors of matrix metalloprotease; SLPI, secretory leukocyte protease inhibitor; BAL, bronchoalveolar lavage; MIP-2, macrophage inflammatory protein-2; CINC, cytokine-induced neutrophil chemoattractant.
Received for publication May 14, 1998. Accepted for publication December 15, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and IL-1. J. Immunol. 149:331.[Abstract]
mediated stimulation of procollagenase production and suppression of biosynthesis of tissue inhibitor of metalloproteinases in rabbit uterine cervical fibroblasts. FEBS Lett. 234:326.[Medline]
2-macroglobulin-bound elastase. Arch. Biochem. Biophys. 260:400.[Medline]
This article has been cited by other articles:
|
|
 |
|
  M. Shyamsundar, S. T. W. McKeown, C. M. O'Kane, T. R. Craig, V. Brown, D. R. Thickett, M. A. Matthay, C. C. Taggart, J. T. Backman, J. S. Elborn, et al. Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy Volunteers Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1107 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P T G Elkington and J S Friedland Matrix metalloproteinases in destructive pulmonary pathology Thorax, March 1, 2006; 61(3): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Kim, K. Burkhart, P. Chen, C. W. Frevert, J. Randolph-Habecker, R. C. Hackman, P. D. Soloway, and D. K. Madtes Tissue Inhibitor of Metalloproteinase-1 Deficiency Amplifies Acute Lung Injury in Bleomycin-Exposed Mice Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Doumas, A. Kolokotronis, and P. Stefanopoulos Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor Infect. Immun., March 1, 2005; 73(3): 1271 - 1274. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Greene, N. G. McElvaney, S. J. O'Neill, and C. C. Taggart Secretory Leucoprotease Inhibitor Impairs Toll-Like Receptor 2- and 4-Mediated Responses in Monocytic Cells Infect. Immun., June 1, 2004; 72(6): 3684 - 3687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Ekekezie, D. W. Thibeault, S. D. Simon, M. Norberg, J. D. Merrill, R. A. Ballard, P. L. Ballard, and W. E. Truog Low Levels of Tissue Inhibitors of Metalloproteinases With a High Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Are Present in Tracheal Aspirate Fluids of Infants Who Develop Chronic Lung Disease Pediatrics, June 1, 2004; 113(6): 1709 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wex, G. Treiber, M. Nilius, M. Vieth, A. Roessner, and P. Malfertheiner Helicobacter pylori-Mediated Gastritis Induces Local Downregulation of Secretory Leukocyte Protease Inhibitor in the Antrum Infect. Immun., April 1, 2004; 72(4): 2383 - 2385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, X. Li, L. Xu, Y. Zhan, S. Yaish-Ohad, J. A. Erhardt, F. C. Barone, and G. Z. Feuerstein Up-Regulation of Secretory Leukocyte Protease Inhibitor (SLPI) in the Brain after Ischemic Stroke: Adenoviral Expression of SLPI Protects Brain from Ischemic Injury Mol. Pharmacol., October 1, 2003; 64(4): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Sallenave, G. A. Cunningham, R. M. James, G. McLachlan, and C. Haslett Regulation of Pulmonary and Systemic Bacterial Lipopolysaccharide Responses in Transgenic Mice Expressing Human Elafin Infect. Immun., July 1, 2003; 71(7): 3766 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Devoogdt, G. Hassanzadeh Ghassabeh, J. Zhang, L. Brys, P. De Baetselier, and H. Revets Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells PNAS, May 13, 2003; 100(10): 5778 - 5782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Eichler, J F M. Bechtel, J. Schumacher, J. A Wermelt, K.-F. Klotz, and C. Bartels A rise of MMP-2 and MMP-9 in bronchoalveolar lavage fluid is associated with acute lung injury after cardiopulmonary bypass in a swine model Perfusion, March 1, 2003; 18(2): 107 - 113. [Abstract] [PDF]
|
|
|
|
 |
|
 V. D. Raykova, M. Glibetic, J. P. Ofenstein, and J. V. Aranda Nitric Oxide-Dependent Regulation of Pro-inflammatory Cytokines in Group B Streptococcal Inflammation of Rat Lung Ann. Clin. Lab. Sci., January 1, 2003; 33(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huber-Lang, E. M. Younkin, J. V. Sarma, N. Riedemann, S. R. McGuire, K. T. Lu, R. Kunkel, J. G. Younger, F. S. Zetoune, and P. A. Ward Generation of C5a by Phagocytic Cells Am. J. Pathol., November 1, 2002; 161(5): 1849 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhang, R. C. M. Simmen, F. J. Michel, G. Zhao, D. Vale-Cruz, and F. A. Simmen Secretory Leukocyte Protease Inhibitor Mediates Proliferation of Human Endometrial Epithelial Cells by Positive and Negative Regulation of Growth-associated Genes J. Biol. Chem., August 9, 2002; 277(33): 29999 - 30009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. I. de Boer Cytokines and Therapy in COPD* : A Promising Combination? Chest, May 1, 2002; 121 (2009): 209S - 218S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Cederqvist, T. Sorsa, T. Tervahartiala, P. Maisi, K. Reunanen, P. Lassus, and S. Andersson Matrix Metalloproteinases-2, -8, and -9 and TIMP-2 in Tracheal Aspirates From Preterm Infants With Respiratory Distress Pediatrics, September 1, 2001; 108(3): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Lentsch, A. Kato, J. T. Saari, and D. A. Schuschke Augmented metalloproteinase activity and acute lung injury in copper-deficient rats Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L387 - L393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Simpson, W. A. H. Wallace, M. E. Marsden, J. R. W. Govan, D. J. Porteous, C. Haslett, and J.-M. Sallenave Adenoviral Augmentation of Elafin Protects the Lung Against Acute Injury Mediated by Activated Neutrophils and Bacterial Infection J. Immunol., August 1, 2001; 167(3): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Warner, C. S. Lewis, L. Beltran, E. M. Younkin, J. Varani, and K. J. Johnson The Role of Metalloelastase in Immune Complex-Induced Acute Lung Injury Am. J. Pathol., June 1, 2001; 158(6): 2139 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Warner, L. Beltran, E. M. Younkin, C. S. Lewis, S. J. Weiss, J. Varani, and K. J. Johnson Role of Stromelysin 1 and Gelatinase B in Experimental Acute Lung Injury Am. J. Respir. Cell Mol. Biol., May 1, 2001; 24(5): 537 - 544. [Abstract] [Full Text]
|
|
|
|
|
|
R.-F. Guo, A. B. Lentsch, R. L. Warner, M. Huber-Lang, J. V. Sarma, T. Hlaing, M. M. Shi, N. W. Lukacs, and P. A. Ward Regulatory Effects of Eotaxin on Acute Lung Inflammatory Injury J. Immunol., April 15, 2001; 166(8): 5208 - 5218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Y. Su, R. H. Jaskot, J. Richards, S. R. Abramson, J. F. Woessner Jr., W.-H. Yu, and K. L. Dreher Induction of pulmonary matrilysin expression by combustion and ambient air particles Am J Physiol Lung Cell Mol Physiol, July 1, 2000; 279(1): L152 - L160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Kernacki, R. Barrett, and L. D. Hazlett Evidence for TIMP-1 Protection Against P. aeruginosa-Induced Corneal Ulceration and Perforation Invest. Ophthalmol. Vis. Sci., December 1, 1999; 40(13): 3168 - 3176. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
